Course of Medicine and Surgery

Transcription

1 Course of Medicine and Surgery 2018/2019 Classes start on March 4th 2019 Classes end on May 15th 2019 Easter Break from April 18th to April 23th 2019 : M. L. Barbaccia Anatomical Pathology: A. Mauriello Systemic Pathology III: M. Andreoni Clinical Practice IV: L. Anemona ROOM Morning 2B4 2B4 2B4 2B4 1 week March 04 March 05 March 06 March 07 March 08 Antibiotic resistance threats and drug discovery void. Polimixins as last resort to treat infections caused by Beta lactam antibiotics and other inhibitors of cell wall synthesis G. MOSCATO multi-drug resistant 4th yr yr pathogen Epidemiology and hostpathogens interactions Carbapenemresistant Enterobacteriaceae and colistinresistant Enterobacteriaceae in healthcare settings New β-lactamase inhibitors and new partners of β-lactamase inhibitors in the clinic: penicillinase, cephalosporinase, and carbapenemase inhibitors in combination with old and new beta-lactams General principles of antimicrobial therapy Antibiotic resistance mechanisms V. MALAGNINO - Syst Pathology III - Fever, Sepsis, Septic Shock

2 Mechanisms of action of antimicrobial agents Updated reports on surveillance of antimicrobial resistance in Europe V. MALAGNINO - Syst Pathology III - Fever, Sepsis, Septic Shock

3 4th yr ROOM Morning 2B4 2B4 2B4 2B4 afternoon 2B3 2B4 2B4 2B4 2 week 18:01 March 11 March 12 March 13 March 14 Antibiotics for resistant Gram positive cocci infections: glicopeptides, lipoglicopeptides, lipopetides Macrolides, azalides and ketolides: their role in community acquired infections M. COMPAGNO - SPIII: SPIII: Meningitis- Encephalitis Lincosamides, streptogramins, oxazolidinones, amphenicols Aminoglycosides, tetracyclines, glycylcyclines Infect Diseases Infect Diseases Sulfonamides, nitroimidazoles, fidaxomicin, nitrofurantoin Fluoroquinolones: updated warnings in the prescribing information M. DE MASI - Syst Pathology III - Bone and Joint Infections C. STINGONE - Syst Pathology III - Sexual Infectious Diseases Anat pathol Anat pathol Anat pathol Anat pathol March 15

4 ROOM Morning 2B4 2B4 2B4 2B4 afternoon 2B3 2B4 2B4 2B4 3 week March 18 March 19 March 20 March 21 March 22 L. FOROGHI - Syst Antiherpes, antiinfluenza and anti- Pathology III - HBV agents Bacterial and Viral Pneumonia Anti- HCV agents: direct acting antivirals 4th yr Anti-mycobacteria agents; drugs for multidrug-resistant TB (TB-MDR) and Extensively resistant TB (XDR-TB) treatment E. TETI -Syst Pathology III - Gastroenterirtis Dyarrhea Antifungal agents SPIII: Blood Diseases SPIII: Blood Diseases E. TETI - Syst Pathology III - Anat pathol 19:00 Hepatitis Anat pathol

5 ROOM Morning 2B4 2B4 2B4 afternoon D16 D16 D16 4 week March 25 March 26 March 27 March 28 March 29 ROOM 4th yr 19:00 SP III Allergology SP III Allergology Blood Diseases Blood Diseases Morning 2B4 2B4 2B4 afternoon D16 D16 5 week April 01 April 02 April 03 V. MALAGNINO - SYST PATHOL III - Urinary Tract April 04 L. COPPOLA - Syst Pathology III - Infect Diseases - Skin and Soft Tissue April 05 4th yr V. MALAGNINO - HIV Anti-HIV agents Anti-malaria and other anti-protozoal agents; anthelminthics General principles of pharmacological anticancer therapy Mechanisms of action of anticancer agents

6 19:00

7 4th yr ROOM Morning 2B4 AnaPat Lab. 2B4 2B4 afternoon 2B4 D16 2B4 2B4 6 week April 08 Resistance mechanisms to anticancer drugs Differences between chemotherapy and targeted agents April 09 April 10 April 11 Basket and umbrella trials; the tissueagnostic drug development approach Targeted therapies and precision medicine in oncology L. CAMPOGIANI - Tubercolosis April 12 Alkylating agents and platinum compounds Anthracyclines and topoisomerase inhibitors Blood Diseases Blood Diseases Medical Statistics To be defined Anat pathol Anat pathol Medical Statistics To be defined Anat pathol Anat pathol SPIII: SPIII: 19:00

8 4th yr ROOM 4th yr ROOM Morning 2B4 AnaPat Lab. 2B4/AnaPat Lab. afternoon D16 2B4 7 week April 15 April 16 April 17 N. CESTA - Syst Pathology III - Endocarditis 19:00 Morning afternoon 8 week April 22 Easter Break April 23 Infect Diseases Infect Diseases Anat pathol Anat pathol SP III SP III April 24 April 18 April 19 Easter Break April 25 April 26 Public Holiday

9 ROOM Morning 2B4 2B4 afternoon 9 week April 29 April 30 May 01 May 02 May 03 4th yr ROOM 4th yr Antimitotic agents; Antimetabolites: hormonal agents for antifolic agents cancer treatment Public Holiday Antipyrimidine and antipurine agents Medical Statistics To be defined Medical Statistics To be defined Monoclonal antibodies for cancer treatment Medical Statistics To be defined Medical Statistics To be defined Morning AnaPat Lab. AnaPat Lab. AnaPat Lab. 1B4 1B4 afternoon 10 week May 06 May 07 May 08 May 09 May 10 Immune checkpoint Kinase inhibitors inhibitors PARP Differentiating inhibitors for BRCA agents; antiangiogenic agents; mutated breast cancer and cisplatin sensitive proteasome and ovarian cancer: the mtor inhibitors; synthetic lethality thalidomide and approach lenalidomide

10 4th yr 4th yr 4th yr 11 week 12 week 13 week May 13 May 14 May 15 May 16 May 17 CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP May 20 May 21 May 22 May 23 May 24 CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP CP May 27 May 28 May 29 May 30 May 31